Hims &Amp; Hers reported a USD 92 million net loss in Q1 2026 as a costly GLP-1 pivot compressed margins. Revenue rose 4%, full-year guidance was raised, and branded weight loss Demand is accelerating.

Key Highlights

  • Net loss widened to USD 92 million in Q1 2026, compared to Net Income of USD 49.5 million in Q1 2025
  • Revenue grew 4% year-over-year to USD 608 million; full-year guidance raised to USD 2.8 to USD 3.0 billion
  • Gross Margin fell to 65% from 73%, largely due to USD 28 million in one-time restructuring charges
  • Hims fulfilled over 125,000 Wegovy shipments within six weeks of launching the Novo Nordisk collaboration
  • Subscribers reached nearly 2.6 million, up 9% year-over-year

A Deliberate Reset, Not a Stumble

Hims & Hers Health (NYSE:HIMS) delivered a financially noisy first quarter in 2026, but management was quick to frame the disruption as intentional. The company reported a GAAP net loss of USD 92.1 million for the three months ended March 31, 2026, translating to an EPS of -USD 0.40 against a consensus forecast of USD 0.01, a stark Reversal from net income of USD 49.5 million in the same period last year. Adjusted EBITDA came in at USD 44.3 million, down from USD 91.1 million, while gross margin compressed from 73% to 65%.

The proximate cause was a strategic pivot in the company's U.S. weight loss Business. In March 2026, Hims discontinued mass Advertising of compounded GLP-1 products and shifted toward branded pharmaceutical solutions, most notably through a new commercial agreement with Novo Nordisk (NYSE:NVO) to distribute Wegovy on its platform. The transition triggered approximately USD 33 million in restructuring charges, including around USD 28 million in inventory write-downs tied to compounded GLP-1 Supply chain Assets facing obsolescence.

Revenue for the quarter came in at USD 608 million, a 4% increase year-over-year, though slightly below analyst consensus. International revenue surged nearly tenfold to USD 78 million, driven by the acquisitions of Zava and Livewell. U.S. revenue, by contrast, declined 8% to USD 530 million, pressured by shorter shipping cadences associated with the new branded product model and a tough comparable period from record weight loss subscriber additions in Q1 2025.

The Branded Bet: Early Signals Are Constructive

Despite the short-term financial noise, the company's early demand indicators around the Novo Nordisk collaboration are notable. Within six weeks of making Wegovy available on its platform, Hims fulfilled more than 125,000 shipments. New subscriber additions in the weight loss category are reportedly tracking above 100,000 per month, a pace the company says exceeds even peak seasonal demand from its New Year and Super Bowl campaigns.

CEO Andrew Dudum described the shift as part of a broader effort to expand the company's addressable market. By moving away from compounded products, which faced mounting legal pressure from Novo Nordisk and regulatory scrutiny, and toward branded GLP-1 medications, Hims is repositioning itself as a distribution and engagement platform for pharmaceutical innovators rather than a manufacturer of cheaper alternatives.

The unit Economics between branded and compounded products are described as roughly comparable on a dollar contribution basis. The structural advantage being pursued is Volume and cross-sell potential. Hims has historically grown new specialties by first driving subscriber scale and then monetising depth of relationship over time.

Cost Structure in Transition

Operating expenses rose sharply in the quarter. General and administrative costs reached USD 109.7 million, up from USD 48.6 million a year ago, driven by Acquisition-related costs, legal settlement charges of USD 15 million, and increased headcount. Technology and development spending rose to USD 46.9 million from USD 29.9 million, reflecting continued Investment in AI infrastructure, a recently launched Labs AI diagnostic agent, and platform re-architecture work.

Free Cash Flow remained positive at USD 53 million, and the company held USD 751 million in cash and short-term investments at quarter-end. Management reiterated a target of returning to GAAP net income profitability in 2027, with near-term focus firmly on growth and free cash flow generation.

For the second quarter, Hims guided revenue of USD 680 million to USD 700 million, representing 25% to 28% year-over-year growth, with adjusted EBITDA of USD 35 million to USD 55 million. Full-year 2026 guidance was raised to USD 2.8 billion to USD 3.0 billion in revenue and USD 275 million to USD 350 million in adjusted EBITDA. The company's longer-term 2030 targets of USD 6.5 billion in revenue and USD 1.3 billion in adjusted EBITDA remain unchanged.

Risk Considerations

The durability of branded GLP-1 demand remains the central variable. Hims is now commercially dependent on Novo Nordisk's pricing and supply decisions in a way it previously was not. Gross margin compression is expected to persist into Q2 as the subscriber base shifts toward one-month shipment cadences. Regulatory clarity on peptide therapies, expected around July 2026, could open a meaningful new category but timelines and commercial readiness remain uncertain.

The Road Ahead

The Q1 loss is largely a function of timing and deliberate restructuring rather than deteriorating fundamentals. Free cash flow remained positive, subscriber growth held steady, and early branded GLP-1 demand has outpaced expectations. The harder question is whether margin recovery arrives on the timeline management is projecting. With EBITDA expected to step up materially in the second half as monthly cohorts compound, and regulatory clarity on peptides potentially opening a new category by July, the next two quarters will be the real test of whether this strategic pivot was a well-executed reset or an optimistic one.